These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9531346)

  • 1. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group.
    Baglin C; Brown K; Luddington R; Baglin T
    Br J Haematol; 1998 Mar; 100(4):764-8. PubMed ID: 9531346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is recurrent venous thromboembolism more frequent in homozygous patients for the factor V Leiden mutation than in heterozygous patients?
    Procare Group
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):523-9. PubMed ID: 12960604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of thrombophilia in deciding on the duration of anticoagulation.
    Bauer KA
    Semin Thromb Hemost; 2004 Dec; 30(6):633-7. PubMed ID: 15630669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial.
    Ridker PM
    Vasc Med; 1998; 3(1):67-73. PubMed ID: 9666536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
    Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Minar E; Lechner K; Kyrle PA
    Thromb Haemost; 1997 Apr; 77(4):624-8. PubMed ID: 9134632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.
    Tzoran I; Papadakis M; Brenner B; Fidalgo Á; Rivas A; Wells PS; Gavín O; Adarraga MD; Moustafa F; Monreal M;
    Am J Med; 2017 Apr; 130(4):482.e1-482.e9. PubMed ID: 27986523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden carriers? A retrospective cohort study.
    Perez Botero J; Ormsby WD; Ashrani AA; McBane RD; Wysokinski WE; Patnaik MM; Lewis BR; Grill DE; Pruthi RK; Heit JA
    Eur J Intern Med; 2016 May; 30():77-81. PubMed ID: 26970916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders.
    Meinardi JR; Middeldorp S; de Kam PJ; Koopman MM; van Pampus EC; Hamulyák K; Prins MH; Büller HR; van der Meer J
    Br J Haematol; 2002 Mar; 116(3):625-31. PubMed ID: 11849222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.
    Eckman MH; Singh SK; Erban JK; Kao G
    Med Decis Making; 2002; 22(2):108-24. PubMed ID: 11958494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?
    Méan M; Limacher A; Stalder O; Angelillo-Scherrer A; Alberio L; Fontana P; Beer HJ; Rodondi N; Lämmle B; Aujesky D
    Am J Med; 2017 Oct; 130(10):1220.e17-1220.e22. PubMed ID: 28606797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FV Leiden mutation and risk of recurrent venous thromboembolism in Serbian population.
    Kovac M; Mikovic D; Antonijevic N; Rakicevic L; Djordjevic V; Radojkovic D; Elezovic I
    J Thromb Thrombolysis; 2008 Jun; 25(3):284-7. PubMed ID: 17549437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy.
    Limdi NA; Beasley TM; Allison DB; Rivers CA; Acton RT
    Blood Cells Mol Dis; 2006; 37(2):100-6. PubMed ID: 16889993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
    Price DT; Ridker PM
    Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis.
    Middeldorp S; Henkens CM; Koopman MM; van Pampus EC; Hamulyák K; van der Meer J; Prins MH; Büller HR
    Ann Intern Med; 1998 Jan; 128(1):15-20. PubMed ID: 9424976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
    Palareti G; Legnani C; Cosmi B; Valdré L; Lunghi B; Bernardi F; Coccheri S
    Circulation; 2003 Jul; 108(3):313-8. PubMed ID: 12847064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.
    Donovan AK; Smith KJ; Ragni MV
    Thromb Res; 2013; 132(6):724-8. PubMed ID: 24112753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.
    De Stefano V; Martinelli I; Mannucci PM; Paciaroni K; Chiusolo P; Casorelli I; Rossi E; Leone G
    N Engl J Med; 1999 Sep; 341(11):801-6. PubMed ID: 10477778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations.
    Brown K; Luddington R; Baglin T
    Br J Haematol; 1998 Oct; 103(1):42-4. PubMed ID: 9792287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.